BaroFold Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron™
News Jun 17, 2008
BaroFold Inc. has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron™ (IFNß-1b).
In published preclinical studies BaroFeron demonstrated enhanced pharmacological properties, both pharmacokinetics and pharmacodynamics, when compared to commercial interferon beta products.
aroFeron has the potential to offer significant benefits to multiple sclerosis patients as these properties have been demonstrated to correlate with lesion formation by MRI measurements and clinical exacerbations.
“BaroFeron is posed to set a new standard for biologics incorporating our novel PreEMT™ technology that produces a product with biopharmaceutical properties that may be superior to conventionally produced proteins,” stated Jeffrey L. Cleland, Ph.D., Vice President of Therapeutic Development. “We believe that MS patients will ultimately benefit from the unique properties of BaroFeron.”
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019